Hemophilia Perspectives Newsletter

Hemophilia Perspectives10_2024 (2)

To view the CME/CNE/CPE accredited activity, please click HERE

Once you’ve read the newsletter, please answer the questions below.

Please enable JavaScript in your browser to complete this form.

Knowledge Check #1

When considering the evolving treatment landscape for treating PwH, how confident are you about the pharmacology and pharmacokinetics underlying non-factor replacement therapies, which may improve hemostasis and ultimately, patient outcomes?

Knowledge Check #2

The development of these new therapeutic agents that act by enhancing coagulation and inhibiting anticoagulant pathways promises to improve the way hemophilia is treated. Which of the following clinical issues is most important to you?

Structuring prophylaxis regimens with non-factor agents
Transitioning patients from factor-replacement therapies to non-factor replacement therapies
Treating PwH with inhibitors with non-factor replacement therapies
Break-through bleeding with non-factor replacement therapies
Muscle bleeds while on non-factor replacement therapies

agents how clinical

Knowledge Check #3

When employing non-factor therapies [NFTs] for PwH, clinicians can:

Monitor patients by measuring aPTT levels weekly
Attain steady-state factor VIII levels
Achieve significantly lower annualized bleeding rates [ABRs], compared with standard of care
Use any current and emerging NFTs in both hemophilia A and B
None of the above